Xuri™ T cell expansion medium
Enables cell expansion of human T lymphocytes. It follows USP <1043> for cell therapy ancillary material.
Xuri™ T cell expansion medium
Enables cell expansion of human T lymphocytes. It follows USP <1043> for cell therapy ancillary material.
Pack size
Overview
- Rapid cell proliferation for faster manufacturing.
- Integrated tubing and ports allowing functionally closed system connections.
- Consistent performance across batches.
- Dedicated cell therapy ancillary product following USP<1043> for ex vivo cultivation.
- Chemically defined and free from any human or animal derived components.
Rapid cell proliferation for faster manufacturing
Xuri T cell expansion medium enables elevated rates of proliferation of viable human T lymphocytes to high cell densities. Cultivation time becomes more flexible, enabling the reach of the desired cell number faster even when working with challenging cells due to donor variability.
Reduce risk with a functionally closed system
Xuri T cell expansion medium is shipped in bags equipped with medical grade PVC tubing and fitted with male and female Luer lock ports, making sure that the bag can be sterile welded to Xuri cellbag bioreactors. This provides the flexibility to add supplements to the bag within a functionally closed system.
Minimize variability for consistent performance
Xuri T cell expansion medium is manufactured under a strict quality management system and the fully validated production process ensures consistency across batches, improving control in achieving the desired cell numbers.
USP <1043> compliance
A smooth submission process is key when dealing with cell therapy regulatory requirements. To help users assess and document production processes, Cytiva supplies Xuri T cell expansion medium with a comprehensive documentation support package that meets USP <1043> ‘ancillary materials for cell, gene, and tissue-engineered products’, within the responsibilities applicable to a supplier.
End user responsibility
Other aspects of USP <1043> will be the responsibility of the end user to assess. Cytiva cannot fulfill USP <1043> in regard to application and therapy specific aspects (e.g., use in finished therapeutic, assessment of removal from a finished therapeutic and possibly biocompatibility, cytotoxicity or adventitious agent testing). The product is chemically defined and free from any human or animal derived components.
